reports
Patrik Ling
- Patrik Ling
Q2 earnings a non-event
BerGenBio reported a Q2 loss. Quarterly earnings reports from development-stage biotech companies are usually a non-event, as these shares are generally driven more by data than by earnings. We reiterate our BUY recommendation but have lowered our target price to NOK32 (NOK36).
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.